EcoDrugPlus

Melatonin Receptor 1a

Ensembl ID : ENSMNEG00000029952
Gene Symbol: MTNR1A
4 Cross references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Melatonin Receptor 1b

Ensembl ID : ENSMNEG00000031635
Gene Symbol: MTNR1B
4 Cross references
107 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Membrane Metalloendopeptidase

Ensembl ID : ENSMNEG00000044087
Gene Symbol: MME
4 Cross references
236 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Methionyl Aminopeptidase 2

Ensembl ID : ENSMNEG00000035522
Gene Symbol: METAP2
4 Cross references
214 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Microtubule Associated Protein Tau

Ensembl ID : ENSMNEG00000043193
Gene Symbol: MAPT
2 Cross references
249 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Microtubule-Associated Protein Tau-Like

Ensembl ID : ENSMNEG00000039464
Gene Symbol: LOC105479529
2 Cross references
247 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSMNEG00000030093
Gene Symbol: MAPK1
3 Cross references
213 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSMNEG00000043177
Gene Symbol: MAPK10
4 Cross references
147 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase 11

Ensembl ID : ENSMNEG00000030261
Gene Symbol: MAPK11
4 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSMNEG00000045205
Gene Symbol: MAPK14
4 Cross references
277 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSMNEG00000031920
Gene Symbol: MAPK3
4 Cross references
198 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSMNEG00000030681
Gene Symbol: MAPK8
4 Cross references
293 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).